March 4, 2020 / 1:15 PM / a month ago

BRIEF-Zosano Pharma Announces FDA Acceptance Of New Drug Application For Qtrypta For The Acute Treatment Of Migraine

March 4 (Reuters) - Zosano Pharma Corp:

* ZOSANO PHARMA ANNOUNCES FDA ACCEPTANCE OF 505(B)(2) NEW DRUG APPLICATION FOR QTRYPTA™ FOR THE ACUTE TREATMENT OF MIGRAINE

* ZOSANO PHARMA - PRESCRIPTION DRUG USER FEE ACT GOAL DATE FOR COMPLETION OF FDA’S REVIEW OF QTRYPTA IS SET FOR OCT 20, 2020 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below